Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

por Yang, C, Li, Z, Bhatt, T, Dickler, M, Giri, D, Scaltriti, M, Baselga, J, Rosen, N, Chandarlapaty, S
Publicado 2017

Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis

por Moss, Nelson S., Singh, Jolene M., Reiner, Anne S., Drago, Joshua Z., Modi, Shanu, Seidman, Andrew D., Chandarlapaty, Sarat, Ross, Dara S.
Publicado 2023

Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling

por She, Qing-Bai, Chandarlapaty, Sarat, Ye, Qing, Lobo, Jose, Haskell, Kathleen M., Leander, Karen R., DeFeo-Jones, Deborah, Huber, Hans E., Rosen, Neal
Publicado 2008

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

por Chandarlapaty, Sarat, Scaltriti, Maurizio, Angelini, Pierdavide, Ye, Qing, Guzman, Marta, Hudis, Clifford A., Norton, Larry, Solit, David B., Arribas, Joaquin, Baselga, Jose, Rosen, Neal
Publicado 2009

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

por Mateo, Lidia, Duran-Frigola, Miquel, Gris-Oliver, Albert, Palafox, Marta, Scaltriti, Maurizio, Razavi, Pedram, Chandarlapaty, Sarat, Arribas, Joaquin, Bellet, Meritxell, Serra, Violeta, Aloy, Patrick
Publicado 2020

Reversible histone glycation is associated with disease-related changes in chromatin architecture

por Zheng, Qingfei, Omans, Nathaniel D., Leicher, Rachel, Osunsade, Adewola, Agustinus, Albert S., Finkin-Groner, Efrat, D’Ambrosio, Hannah, Liu, Bo, Chandarlapaty, Sarat, Liu, Shixin, David, Yael
Publicado 2019

Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer

por Mayne, Christopher G., Toy, Weiyi, Carlson, Kathryn E., Bhatt, Trusha, Fanning, Sean W., Greene, Geoffrey L., Katzenellenbogen, Benita S., Chandarlapaty, Sarat, Katzenellenbogen, John A., Tajkhorshid, Emad
Publicado 2021

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(−) advanced breast cancer: results from BOLERO-2

por Moynahan, Mary Ellen, Chen, David, He, Wei, Sung, Patricia, Samoila, Aliaksandra, You, Daoqi, Bhatt, Trusha, Patel, Parul, Ringeisen, Francois, Hortobagyi, Gabriel N, Baselga, Jose, Chandarlapaty, Sarat
Publicado 2017

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody

por Lopez-Albaitero, Andres, Xu, Hong, Guo, Hongfen, Wang, Linlin, Wu, Zhihao, Tran, Hoa, Chandarlapaty, Sarat, Scaltriti, Maurizio, Janjigian, Yelena, de Stanchina, Elisa, Cheung, Nai-Kong V.
Publicado 2017

PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition

por Castel, Pau, Ellis, Haley, Bago, Ruzica, Toska, Eneda, Razavi, Pedram, Carmona, F. Javier, Kannan, Srinivasaraghavan, Verma, Chandra S., Dickler, Maura, Chandarlapaty, Sarat, Brogi, Edi, Alessi, Dario R., Baselga, José, Scaltriti, Maurizio
Publicado 2016

KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function

por Gala, Kinisha, Li, Qing, Sinha, Amit, Razavi, Pedram, Dorso, Madeline, Sanchez-Vega, Francisco, Chung, Young Rock, Hendrickson, Ronald, Hsieh, James J., Berger, Michael, Schultz, Nikolaus, Pastore, Alessandro, Abdel-Wahab, Omar, Chandarlapaty, Sarat
Publicado 2018

Androgen Receptor Splicing Variant-7 in Breast Cancer: Clinical and Pathologic Correlations

por Ferguson, Donna C., Mata, Douglas A., Tay, Timothy KY., Traina, Tiffany A., Gucalp, Ayca, Chandarlapaty, Sarat, D’Alfonso, Timothy M., Brogi, Edi, Mullaney, Kerry, Ladanyi, Marc, Arcila, Maria E., Benayed, Ryma, Ross, Dara S.
Publicado 2022

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

por Serra, V, Scaltriti, M, Prudkin, L, Eichhorn, P J A, Ibrahim, Y H, Chandarlapaty, S, Markman, B, Rodriguez, O, Guzman, M, Rodriguez, S, Gili, M, Russillo, M, Parra, J L, Singh, S, Arribas, J, Rosen, N, Baselga, J
Publicado 2011

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

por Jhaveri, Komal, Wang, Rui, Teplinsky, Eleonora, Chandarlapaty, Sarat, Solit, David, Cadoo, Karen, Speyer, James, D’Andrea, Gabriella, Adams, Sylvia, Patil, Sujata, Haque, Sofia, O’Neill, Tara, Friedman, Kent, Esteva, Francisco J., Hudis, Clifford, Modi, Shanu
Publicado 2017

In situ single cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2(+) breast cancer

por Janiszewska, Michalina, Liu, Lin, Almendro, Vanessa, Kuang, Yanan, Paweletz, Cloud, Sakr, Rita A., Weigelt, Britta, Hanker, Ariella B., Chandarlapaty, Sarat, King, Tari A., Reis-Filho, Jorge S., Arteaga, Carlos L., Park, So Yeon, Michor, Franziska, Polyak, Kornelia
Publicado 2015

A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer

por Dorso, M., Patel, Payal T., Pankov, Aleksandr, Boyer, Jacob A., Soni, Rajesh K., Del Priore, Isabella S., Hayatt, Omar, Kulick, Amanda, Hagen, Connor J., de Stanchina, Elisa, Junttila, Melissa R., Daemen, Anneleen, Friedman, Lori S., Hendrickson, Ronald C., Chandarlapaty, Sarat
Publicado 2023

ESR1 ligand binding domain mutations in hormone-resistant breast cancer

por Toy, Weiyi, Shen, Yang, Won, Helen, Green, Bradley, Sakr, Rita A., Will, Marie, Li, Zhiqiang, Gala, Kinisha, Fanning, Sean, King, Tari A., Hudis, Clifford, Chen, David, Taran, Tetiana, Hortobagyi, Gabriel, Greene, Geoffrey, Berger, Michael, Baselga, Jose, Chandarlapaty, Sarat
Publicado 2013

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

por Hudis, Clifford, Swanton, Charles, Janjigian, Yelena Y, Lee, Ray, Sutherland, Stephanie, Lehman, Robert, Chandarlapaty, Sarat, Hamilton, Nicola, Gajria, Devika, Knowles, James, Shah, Jigna, Shannon, Keith, Tetteh, Ernestina, Sullivan, Daniel M, Moreno, Carolina, Yan, Li, Han, Hyo Sook
Publicado 2013

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway

por Smith, Alison E., Ferraro, Emanuela, Safonov, Anton, Morales, Cristina Bernado, Lahuerta, Enrique J. Arenas, Li, Qing, Kulick, Amanda, Ross, Dara, Solit, David B., de Stanchina, Elisa, Reis-Filho, Jorge, Rosen, Neal, Arribas, Joaquín, Razavi, Pedram, Chandarlapaty, Sarat
Publicado 2021

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab

por Ferraro, Emanuela, Singh, Jasmeet, Patil, Sujata, Razavi, Pedram, Modi, Shanu, Chandarlapaty, Sarat, Barrio, Andrea V., Malani, Rachna, Mellinghoff, Ingo K., Boire, Adrienne, Wen, Hannah Y., Brogi, Edi, Seidman, Andrew D., Norton, Larry, Robson, Mark E., Dang, Chau T.
Publicado 2022